DCTD Programs
Last Updated: 06/02/2022
2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Schedule of DCTD Presentations
DCTD-supported research will be presented at the ASCO Annual Meeting 
from June 3-7, 2022. The following tables include the oral and
poster sessions containing DCTD staff speakers and co-authors.
Oral Sessions
| Title | Link Date/Time |
|---|---|
| ASCO Town Hall: The Future of the Conduct of Clinical Trials After COVID-19; CTEP Perspective Speaker: Margaret Mooney, MD, MS |
Education Session
June 4, 4:00 pm EDT |
| COVID-19 and Cancer: Advantages and Disadvantages of Immunotherapy: Immune checkpoint inhibitors and COVID-19: What are the risks of immune-related adverse events in patients with COVID-19? Speaker: Elad Sharon, MD, MPH |
Education Session
June 6, 12:30 pm EDT |
Poster Sessions
CSClinical Science Symposium; eePublication; OAOral Abstract Session; PPoster Presentation; PDPoster Discussion Session
| Title | Link Abstract # |
|---|---|
| Racial/ethnic disparities in locoregional recurrence in hormone-receptor positive node-negative breast cancer patients enrolled in the TAILORx trial | PD515
|
| Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma | P2035
|
| The interim result of a phase I/II study of nivolumab with or without ipilimumab in combination with multi-fraction stereotactic radiosurgery for recurrent, high-grade, radiation-relapsed meningioma | P2068
|
| Major adverse cardiac events (MACE) with immune checkpoint inhibitor (ICI)-based therapies for cancer: A pooled analysis of investigational clinical trials sponsored by the National Cancer Institute Cancer Therapy Evaluation Program (NCI-CTEP) in the United States and Canada | OA2508
|
| Molecular predictors of response among patients with MMRd tumors treated on NCI-MATCH Arm Z1D | P2616
|
| Immune checkpoint inhibitor-induced diabetes mellitus across NCI trials | P2668
|
| Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J) | PD3009
|
| Phase II study of vismodegib in patients with SMO or PTCH1 mutated: Results from NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol T | PD3010
|
| Safety, pharmacodynamic, and clinical response evaluation of nilotinib and paclitaxel in adults with refractory solid tumors Presenter: Sarah Shin, MD |
P3026
|
| Blood-based detection of actionable alterations from NCI-MATCH patients with no tissue results | P3035
|
| Phase 2 of trametinib plus radioiodine in RAS-mutant and wild-type, radioiodine-refractory thyroid cancer (ETCTN9446) | P6089
|
| Bringing experimental therapeutics clinical trials network (ETCTN) to underrepresented population | P6542
|
| Representatives of patients enrolled in the Lung Cancer Master Protocol (Lung-MAP) | P6543
|
| Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512) | OA9502
|
| Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers | OA9507
|
| Tazemetostat in patients with tumors with alterations in EZH2 or the SWI/SNF complex: Results from NCI-COG Pediatric MATCH trial Arm C (APEC1621C) | PD10009
|
| Biomarkers Beyond Histology in Contemporary Sarcoma Clinical Trials | CS11509
|
| A phase 2 study of anti-PD-L1 antibody (atezolizumab) in grade 2 and 3 chondrosarcoma | P11528
|
| Extended progression-free survival and long-term safety of nirogacestat in patients with desmoid tumors Presenter: Geraldine O’Sullivan Coyne, MD, PhD |
P11545
|
| Comparison of AYA versus non-AYA ovarian cancer genomic landscape in NCI-MATCH trial Presenter: Hari Sankaran, PhD |
eE17617
|
| Phase I study of entinostat (Ent), atezolizumab (A), carboplatin (C), and etoposide (E) in previously untreated extensive-stage small cell lung cancer (ES-SCLC), ETCTN 10399 | eE20606
|
| Results of the DIAL study (NCI 10089), a randomized phase 2 trial of Varlilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL) | PLBA7564
|
| A phase I/II trial evaluating the safety and efficacy of eribulin in combination with Copanlisib in patients with metastatic triple-negative breast cancer (TNBC) | PTPS1128
|
| A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma | PTPS3174
|
| A phase 2 study of bevacizumab, erlotinib, and atezolizumab in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) associated or sporadic papillary renal cell cancer (pRCC) | PTPS4604
|
Staff Kiosk Schedule — Booth #4043
| Date | Time | Presenter |
|---|---|---|
| June 4 | 11:00 AM - 1:00 PM | Lori Henderson, PhD Cancer Therapy Evaluation Program |
| June 5 | 9:00 AM - 11:00 AM | Sharad Verma, PhD Developmental Therapeutics Program |
| 1:00 PM - 3:00 PM | Marc S. Ernstoff, MD Developmental Therapeutics Program |
|
| 3:00 PM - 5:00 PM | Sundar Venkatachalam, PhD Developmental Therapeutics Program |
|
| June 6 | 9:00 AM - 11:00 AM | Sharad Verma, PhD Developmental Therapeutics Program |
| 11:00 AM - 1:00 PM | Sundar Venkatachalam, PhD Developmental Therapeutics Program |